3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma SEGN

Seegnal Inc.

SEGN TSXV Biotech & Pharma

Stock factsheet

TickerSEGN
ExchangeTSXV
ISIN
WKN
SectorBiotech & Pharma
Size class Nano Cap
Market capitalisation 9 Mio. USD As of 2026-08-04

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

Seegnal Inc. (TSXV: SEGN) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company's SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age, and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing, and advance a more personalized standard of patient care. Seegnal's technology is deployed across healthcare settings and is used by more than 15,000 clinicians in daily practice.

Company description as published by the issuer via TMX Money.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
Seegnal Inc.SEGN TSXV9 Mio. USD
1CM Inc EPICCSE 9 Mio. USD
Rapid Dose Therapeutics Corp. DOSECSE 9 Mio. USD
Rhelion Life Sciences Corp. RELHCSE 9 Mio. USD
Hemostemix Inc. HEMTSXV 9 Mio. USD
AI-ML Innovations Inc. AIMLCSE 9 Mio. USD
InnoCan Pharma Corporation INNOCSE 9 Mio. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.